Etonogestrel Implants Protect Ovarian Reserve Function in Systemic Lupus Erythematosus

• Status: Not yet recruiting
• Trial end date: 2025-10-31
• Target enrollment: 0
• Participant gender: Female

Summary

This clinical trial aims to test in female patients with systemic lupus erythematosus (SLE). The main question it seeks to answer is whether etonogestrel implants can protect ovarian reserve function in patients with SLE. Participants will be randomly divided into a test group and a control group. The test group will be implanted subcutaneously with etongestrel for one year. Researchers won't intervene in the control group. After three months of drug-eluting, researchers will compare measures of ovarian reserve function in the test and control groups to see if etonogestrel implants can protect ovarian reserve function in patients with SLE.

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Sixth Affiliated Hospital, Sun Yat-sen University
• Treatments: Etonogestrel

Criteria

Inclusion Criteria:

1. Systemic lupus erythematosus was confirmed

2. 18-37 years old

Exclusion Criteria:

1. History of sex chromosome abnormalities

2. History of abnormal thyroid function

3. History of abnormal adrenal function

4. History of pituitary disease

5. History of sexual hormone drug use in the past 3 months

6. History of ovarian tumors or invasive ovarian operations

7. Pregnancy

8. Have a birth plan in the next 1 year

9. Ovarian failure